Regeneron Pharmaceuticals Announced New Analyses Of Eylea HD (Aflibercept) Injection 8 Mg And Eylea Injection 2 Mg Will Be Presented At The Annual Meeting Of The European Society Of Retina Specialists
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals will present new analyses of Eylea HD and Eylea injections at the European Society of Retina Specialists meeting. The presentations will include post-hoc analyses of the PULSAR trial for Eylea HD in wet age-related macular degeneration, focusing on disease activity criteria, fluid control, and safety.
September 11, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals is set to present new analyses of Eylea HD at a major retina specialists meeting, which could influence perceptions of its efficacy and safety in treating wet age-related macular degeneration.
The presentation of new analyses at a major medical meeting could positively impact Regeneron's stock by enhancing the perceived efficacy and safety of Eylea HD, potentially leading to increased adoption and sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90